- Getinge’s net sales for the second quarter reached SEK8.24 billion, aligning closely with the projected SEK8.2 billion.
- The Acute Care Therapies segment reported net sales of SEK4.48 billion.
- Life Science net sales amounted to SEK1.12 billion, exceeding the forecast of SEK1.07 billion.
- Surgical Workflows segment achieved net sales of SEK2.63 billion, slightly below the estimate of SEK2.76 billion.
- There was an organic revenue growth of 4.1% during this period.
- Adjusted operating profit stood at SEK895 million, surpassing the estimated SEK859.9 million.
- Operating profit was recorded at SEK867 million, significantly higher than the forecasted SEK733.4 million.
- Orders received during the quarter totaled SEK8.36 billion.
- Getinge’s gross margin reached 47.8%, which was above the estimated 46.8%.
- Analyst ratings include 7 buys, 6 holds, and 1 sell recommendation.
A look at Getinge AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts evaluating the Smartkarma Smart Scores for Getinge AB have given the company a positive outlook across various factors. With a strong Value score of 4, it suggests that Getinge AB is considered attractively valued compared to its peers. This is further reinforced by a solid Dividend score of 4, indicating a healthy dividend payout for investors. While the Growth and Resilience scores stand at 3 each, showcasing a moderate growth potential and resilience in the face of challenges, the Momentum score of 2 suggests a relatively slower momentum compared to other factors.
Overall, based on the provided Smart Scores, Getinge AB appears to be a fundamentally sound company with good value propositions and dividend returns. Investors may find the company’s stability and growth prospects appealing, although the momentum factor indicates a more cautious approach. Getinge AB‘s core focus on developing, manufacturing, and selling equipment for sterilization and disinfection, targeting various sectors such as pharmaceuticals, hospitals, dental clinics, and laboratories globally, positions it favorably for long-term success in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
